S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases

Duguet, Fanny; Ortega-Ferreira, Céline; Fould, Benjamin; Darville, Hélène; Berger, Sylvie; Chomel, Agnès; Leclerc, Grégory; Kisand, Kai; Haljasmägi, Liis; Hayday, Adrian C; Desvaux, Emiko; Nony, Emmanuel; Moingeon, Philippe; De Ceuninck, Frédéric

1-s2.0-S2589909021000137-main (1).pdf (2.25 MB)

S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases

journal contribution

posted on 2021-03-17, 14:20 authored by Fanny Duguet, Céline Ortega-Ferreira, Benjamin Fould, Hélène Darville, Sylvie Berger, Agnès Chomel, Grégory Leclerc, Kai Kisand, Liis Haljasmägi, Adrian C Hayday, Emiko Desvaux, Emmanuel Nony, Philippe Moingeon, Frédéric De Ceuninck

No description supplied

Funding

Crick (Grant ID: 10093, Grant title: Hayday FC001093)

History

Publisher DOI

https://doi.org/10.1016/j.jtauto.2021.100093

S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases

Funding

Crick (Grant ID: 10093, Grant title: Hayday FC001093)

History

Publisher DOI

Usage metrics

Categories

Keywords

Licence

Exports